Waltham, Mass.-based Alere Inc. is discontinuing its Inratio and Inratio 2 PT/INR blood monitoring devices after the FDA said a study of the products' software enhancements was inadequate. The company's stock fell more than 3 percent on the news, which will result in charges of between $70 million and $90 million this year. Read More
The U.S. Federal Trade Commission requested more information about the impending $25 billion merger of St. Jude Medical Inc. and Abbott Laboratories, meaning the earliest date at which the deal can close has been extended by 30 days. Read More